This article is more than 5 years old. Information may no longer be current.

VIDEO: PCKS9 inhibitors effective for reducing CV risk

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — Robert Eckel, MD, professor of medicine in the divisions of endocrinology, metabolism and diabetes and of cardiology at the University of Colorado School of Medicine, discusses his presentation on the use of PCKS9 inhibitors in clinical practice.

According to Eckel, years ago, there were very few drugs for patients at risk for cardiovascular disease, but there is now substantial evidence that statins reduce CV risk.

Eckel said it is important to understand the 2013 American Heart Association and American College of Cardiology guidelines on statins before prescribing them to patients.